- Telehealth Visits
- Insurance plan information
Darren Pan, MD
He | Him | HisHematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information
Darren Pan, MD
He | Him | HisHematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Darren Pan is a hematologist-oncologist who provides care in both the clinic and the hospital for patients with multiple myeloma or other blood cancers. His treatment expertise includes bone marrow (stem cell) transplantation and advanced cellular therapies, such as CAR T-cell therapy.
Pan's research focuses on identifying cutting-edge options for patients with multiple myeloma. He is particularly interested in immunotherapy (treatments that help the patient's own immune system recognize and fight cancer). He also studies high-risk multiple myeloma, a category of this cancer in which certain features make the disease more aggressive and difficult to treat.
Pan earned his medical degree from the David Geffen School of Medicine at UCLA. At the Icahn School of Medicine at Mount Sinai, he completed a residency in internal medicine and a fellowship in hematology and medical oncology.
Education & training
Board certification
- Hematology, American Board of Internal Medicine/Hematology
- Internal Medicine, American Board of Internal Medicine
Residency
- Internal Medicine, Icahn School of Medicine at Mount Sinai
Degree
- MD, UCLA David Geffen School of Medicine
My expertise
Specialties
Locations
My research
Clinical trials
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisOpens in a new window
Recruiting
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.